Radioimmunotherapy (RIT) aims to selectively deliver radionuclides emitting α-particles, β-
particles or Auger electrons to tumors by conjugation to monoclonal antibodies (mAbs) that …

Somatostatin and its analogues bind to somatostatin receptors (sst) 1 through 5 that are
overexpressed in neuroendocrine neoplasms such as gastroenteropancreatic (GEP) …

Background Auger electron emitters that can be targeted into DNA of tumour cells represent
an attractive systemic radiation therapy goal. In the situation of DNA-associated decay, the …

CD74 is an integral membrane protein that functions as a MHC class II chaperone.
Moreover, it has recently been shown to have a role as an accessory-signaling molecule …

Auger electron emitters such as 125I have a high linear energy transfer and short range of
emission (< 10 μm), making them suitable for treating micrometastases while sparing normal …

Over the past 40 years, a small and highly committed group of scientists has pursued
various investigations focused on understanding the physical phenomena underlying the …

Purpose: IMMU-110 is a drug immunoconjugate composed of doxorubicin conjugated to the
humanized anti-CD74 monoclonal antibody, hLL1, at a doxorubicin/monoclonal antibody …

Several radionuclides used in medical imaging emit Auger electrons, which, depending on
the targeting strategy, either may be exploited for therapeutic purposes or may contribute to …

Introduction Despite its desirable half-life and low energy Auger electrons that travel further
than for other radionuclides, 67 Ga has been neglected as a therapeutic radionuclide. Here …

The humanized anti-CD74 monoclonal antibody (mAb) hLL1 is under evaluation as a
therapeutic agent. The effects of hLL1—at times in comparison with the CD20 mAb rituximab …